UroGen Pharma (URGN) Gross Margin (2017 - 2026)
UroGen Pharma (URGN) posted quarterly Gross Margin of 91.88% for Q1 2026, up 338.0% year-on-year from 20.98% in Q1 2025, and up 0.62% on a QoQ basis from 91.31% in Q4 2025.
UroGen Pharma (URGN) Gross Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Gross Margin for 10 consecutive years, with 91.88% the latest figure, recorded in Q1 2026.
- Quarterly Gross Margin rose 338.0% year-over-year to 91.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.85% (up 17.0% YoY) and the FY2025 annual result came in at 88.66%, down 151.0% from the prior year.
- Gross Margin advanced to 91.88% in Q1 2026 per URGN's latest filing, from 91.31% in the prior quarter.
- Over the last five years, Gross Margin for URGN reached as high as 91.88% in Q1 2026 and fell as low as 85.34% in Q2 2025.
- A 5-year average of 88.98% and a median of 88.76% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin soared 397 bps — and 2025, when it plunged 446 bps.
- Year by year, Gross Margin stood at 87.49% in 2022, then gained by 3 bps to 90.28% in 2023, then fell by 0 bps to 89.94% in 2024, then gained by 2 bps to 91.31% in 2025, then climbed by 1 bps to 91.88% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 91.88%, 91.31%, and 88.07% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | 91.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.88% |
| Dec 31, 2025 | 91.31% |
| Sep 30, 2025 | 88.07% |
| Jun 30, 2025 | 85.34% |
| Mar 31, 2025 | 88.50% |
| Dec 31, 2024 | 89.94% |
| Sep 30, 2024 | 90.27% |
| Jun 30, 2024 | 89.80% |
| Mar 31, 2024 | 90.80% |
| Dec 31, 2023 | 90.28% |
| Sep 30, 2023 | 88.65% |
| Jun 30, 2023 | 88.44% |
| Mar 31, 2023 | 86.83% |
| Dec 31, 2022 | 87.49% |
| Sep 30, 2022 | 87.45% |
| Jun 30, 2022 | 88.88% |
| Mar 31, 2022 | 88.76% |
| Dec 31, 2021 | 90.18% |
| Sep 30, 2021 | 89.04% |
| Jun 30, 2021 | 89.05% |